Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice | Zendy

Zhipeng You | Zendy; Jacques Genest | Zendy; Pierre-Olivier Barrette | Zendy; Anouar Hafiane | Zendy; David J. Behm | Zendy; Pedro D’Orléans-Juste | Zendy; Adel Schwertani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice

Author(s) -

Zhipeng You,

Jacques Genest,

Pierre-Olivier Barrette,

Anouar Hafiane,

David J. Behm,

Pedro D’Orléans-Juste,

Adel Schwertani

Publication year - 2012

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.252973

Subject(s) - urotensin ii , hyperlipidemia , endocrinology , medicine , knockout mouse , apolipoprotein b , receptor , ldl receptor , lipoprotein , biology , cholesterol , diabetes mellitus

Urotensin II (UII) is a potent vasoactive peptide that binds to the urotensin receptor-coupled receptor-14 (known as UT) and exerts a wide range of actions in humans and experimental animals. We tested the hypothesis that UII gene deletion or UT blockade ameliorate experimental atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research